Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04921943 · ClinicalTrials.gov registry record · Phase 4

Hypertonic Saline for MAC

A Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection, sponsored by Oregon Health and Science University.

Recruiting
Registry status
Phase 4
Development phase
50
Enrollment target
3
Study locations

NCT04921943 is a Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 50 participants. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04921943, a Phase 4 study of Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection, is actively recruiting participants, sponsored by Oregon Health and Science University.

RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Interventions

  • DRUG Azithromycin
  • DRUG Hypertonic saline
  • DRUG Ethambutol
  • DRUG Rifampin

Study Locations (3)

New York

  • NYU Langone Health - New York

Oregon

  • Oregon Health & Science University - Portland

Ontario

  • University Health Network - Toronto

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-05-18
Est. Completion 2025-12-31
Phase Phase 4

What the Registry Record Tells You About NCT04921943

The ClinicalTrials.gov registry entry for NCT04921943 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nontuberculous Mycobacterial Lung Disease appearing as the primary indexed condition, and to 4 interventions - of which Azithromycin is the first listed.

NCT04921943 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Oregon, Ontario.

Frequently Asked Questions

What is clinical trial NCT04921943 about?

NCT04921943 is a clinical study titled "Hypertonic Saline for MAC". The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

What is the current status of trial NCT04921943?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-05-18. Estimated completion is 2025-12-31.

What conditions does trial NCT04921943 study?

This clinical trial studies the following conditions: Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection.

What interventions are being tested in trial NCT04921943?

The interventions under investigation include: Azithromycin (DRUG), Hypertonic saline (DRUG), Ethambutol (DRUG), Rifampin (DRUG).

Who is sponsoring clinical trial NCT04921943?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04921943 being conducted?

This trial has 3 study locations across New York, Oregon, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nontuberculous Mycobacterial Lung Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.